BridgeMD
Tests treatment safety and results for Acute Ischemic Stroke
Official title Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)
ClinicalTrials.gov ID: NCT06101667
What this study is testing
What is Best medical management?
Best medical management is an investigational medicine, given as a treatment applied to the skin, being studied as a potential treatment for acute ischemic stroke.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of this study is to assess the efficacy and safety of endovascular treatment versus medical management in patients with acute basilar artery occlusion with extended time window of 24-72 hours from onset.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age≥18 years
- Acute basilar artery occlusion confirmed by CTA, MRA, or DSA
- Pre-stroke mRS of 0-2
- NIHSS score ≥ 10 before randomization
- Time interval from symptom onset (or last known well) to randomization within 24-72 hours
You likely can't join if
- Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization
- Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging
- CT or MRI evidence of intracranial tumor (except small meningioma and cerebral aneurysm \< 3mm in diameter)
- Known or highly suspected chronic occlusion of basilar artery
- History of contraindication for contrast medium (except mild rash)
- Current pregnant or breast-feeding
See the full eligibility criteria
- Age≥18 years
- Acute basilar artery occlusion confirmed by CTA, MRA, or DSA
- Pre-stroke mRS of 0-2
- NIHSS score ≥ 10 before randomization
- Time interval from symptom onset (or last known well) to randomization within 24-72 hours
- Diffusion-weighted imaging(DWI)-based pc-ASPECTS ≥ 6 and Pons-Midbrain Index (PMI) ≤3
- Time from completion of DWI imaging to randomization is ≤3 hours
- Each patient or their legal representative must provide written informed consent before enrolment
- Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization
- Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging
- CT or MRI evidence of intracranial tumor (except small meningioma and cerebral aneurysm \< 3mm in diameter)
- Known or highly suspected chronic occlusion of basilar artery
- History of contraindication for contrast medium (except mild rash)
- Current pregnant or breast-feeding
- Known to have dementia or psychiatric disease unable to complete neurological assessment and follow-up
- Life expectancy is less than 3 months
- Enrolled in another drug or device trial or expected to participate in another drug or device treatment trial within the following 3 months.
- Any other condition (in the opinion of the site investigator) that inappropriate to participate this study
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.